anti-inflammatoty and immuno-therapy - versus placebo - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.83 [0.66, 1.05]< 11%9 studies (9/-)94.3 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 0.65 [0.35, 1.22]< 10%1 study (1/-)90.9 %NAnot evaluable crucial-
deaths 0.82 [0.66, 1.02]< 18%13 studies (13/-)96.3 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.04 [0.80, 1.35]< 10%4 studies (4/-)38.6 %some concernnot evaluable moderatecrucial-
clinical improvement 1.08 [0.94, 1.24]> 116%9 studies (9/-)85.3 %some concernserious moderateimportant-
clinical improvement (14-day) 1.29 [0.69, 2.41]> 166%2 studies (2/-)78.3 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.34 [1.00, 1.81]> 10%5 studies (5/-)97.4 %some concernserious moderateimportant-
clinical improvement (time to event analysis only) 1.03 [0.93, 1.14]> 10%5 studies (5/-)71.7 %some concernnot evaluable moderateimportant-
death or ventilation 0.92 [0.70, 1.22]< 10%2 studies (2/-)71.5 %some concernnot evaluable moderateimportant-
hospital discharge 1.16 [0.70, 1.92]> 159%2 studies (2/-)72.2 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.79 [0.53, 1.16]< 17%6 studies (6/-)88.7 %lownot evaluable highimportant-
ICU admission 0.57 [0.36, 0.91]< 10%2 studies (2/-)99.1 %some concernnot evaluable moderatenon important-
recovery 1.57 [0.77, 3.20]> 10%1 study (1/-)89.3 %NAnot evaluable non important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 0.94 [0.76, 1.15]< 15%7 studies (7/-)72.7 %some concernnot evaluable moderateimportant-
superinfection 0.81 [0.49, 1.34]< 10%1 study (1/-)79.2 %NAnot evaluable important-
adverse events 1.08 [0.83, 1.39]< 113%7 studies (7/-)28.4 %some concernserious moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.